Multidrug-resistant tuberculosis in child successfully treated with 9-month drug regimen by Achar, J et al.
Multidrug-Resistant  
Tuberculosis in Child  
Successfully Treated with 
9-Month Drug Regimen
Jay Achar, Catherine Berry, Krzysztof Herboczek, 
Nargiza Parpieva, Mirzagaleb N. Tillyashaykhov, 
Zinaida N. Tigay, Atadjan Khamraev,  
Kalyan Velivela, James A. Seddon,  
Philipp du Cros
Author affiliations: Médecins Sans Frontières, London, UK  
(J. Achar, K. Herboczek, J.A. Seddon, P. du Cros); Médecins Sans 
Frontières, Tashkent, Uzbekistan (C. Berry, K. Velivela); Ministry 
of Health, Tashkent (N. Parpieva, M.N. Tillyashaykhov); Ministry 
of Health, Nukus, Uzbekistan (Z.N. Tigay, A. Khamraev); Imperial 
College London, London (J.A. Seddon)
DOI: http://dx.doi.org/10.3201/eid2111.151119
To the Editor: Approximately 480,000 persons ac-
quired multidrug-resistant tuberculosis (MDR TB) in 2013 
(1). Of the 32,000 children who acquire MDR TB annually, 
few are identified and administered appropriate treatment 
(2). World Health Organization (WHO)–recommended 
treatment for MDR TB lasts 20–24 months, including 8 
months of daily drug injections (3). Because many children 
have paucibacillary TB, a shorter protocol may be suffi-
cient, especially for early or nonsevere disease.
In Bangladesh, 87% of MDR TB patients who received 
a 9-month regimen had a favorable outcome; compared 
with patients who received the WHO regimen, fewer had 
adverse events or were lost to follow-up (4,5). A random-
ized controlled trial of this regimen is ongoing (6); how-
ever, the trial excludes children, and no detailed data are 
available for use of this regimen in children. The regimen is 
being implemented in several countries under operational 
research conditions (7).
Along with the Ministry of Health of Uzbekistan, and 
in accordance with WHO advice (8), Médecins Sans Fron-
tières investigated the efficacy, tolerability, and safety of 
the shortened regimen in Karakalpakstan, Uzbekistan (9), 
where rates of second-line drug resistance are high (1) and 
katG-mediated isoniazid resistance predominates. Unlike 
the Bangladesh study (4), the Karakalpakstan study used 
moxifloxacin instead of gatifloxacin and included sched-
uled electrocardiograms (ECGs) and graded assessments of 
side effects to monitor for safety, including cardiac toxic-
ity. All drugs in the regimen were previously used safely in 
children (10). For children, limited data are available re-
garding use of 2 new TB drugs, bedaquiline and delamanid; 
thus, the shortened regimen could represent the best oppor-
tunity to improve their outcomes and access to treatment. 
We report the successful treatment of MDR TB in a child 
who received the 9-month drug regimen. This retrospective 
research fulfilled Médecins Sans Frontières Ethics Review 
Board criteria for analysis of existing program data. Written 
informed consent was provided by the child and his parents.
In November 2013, a 14-year-old boy in Karakalpak-
stan received a diagnosis of pulmonary MDR TB after 
seeking medical care for a sore throat without cough, fever, 
weight loss, or major concurrent conditions. His mother (a 
close contact) had experienced symptoms of pulmonary TB 
since 2011 and, after a period of self-treatment, received a 
diagnosis of MDR TB with confirmed absence of preex-
tensively or extensively drug-resistant TB; she completed 
appropriate treatment in September 2013. In accordance 
with national guidelines, the boy did not receive treatment 
for latent TB.
Clinical examination of the boy (weight 43 kg, body 
mass index 17.2 kg/m2) was unremarkable and showed no 
signs of extrapulmonary disease. A chest radiograph showed 
a left midzone interstitial infiltrate. Sputum sample testing 
(Xpert MTB/RIF; Cepheid, Sunnyvale, CA, USA) con-
firmed rifampin-resistant Mycobacterium tuberculosis. Spu-
tum smear microscopy and liquid-based culture (BACTEC 
MGIT 960; Becton Dickinson, Franklin Lakes, NJ, USA) 
were negative. Baseline biochemical, hematologic, and ECG 
results were within normal limits. Serologic test results were 
negative for HIV and hepatitis B and C viruses.
Together, a history consistent with TB disease, radio-
graphic evidence, and molecular testing results were con-
sidered sufficient indication for treatment of MDR TB. Af-
ter psychosocial counseling and health education sessions, 
the boy, with his family’s agreement, consented to daily 
outpatient treatment with isoniazid (400 mg), ethambutol 
(800 mg), pyrazinamide (1,600 mg), prothionamide (500 
mg), moxifloxacin (400 mg), capreomycin (750 mg), and 
clofazimine (100 mg) beginning in December 2013.
Treatment initiation was complicated by drug-associ-
ated nausea and vomiting, headache, tinnitus, and abdomi-
nal pain. Despite early aggressive management in line with 
study protocols, occasional vomiting continued. Intensive 
counseling ensured good adherence; only 3 days were 
missed. Corrected QT prolongation was excluded by use of 
ECG monitoring during treatment initiation.
After 4 months of treatment, the boy’s sputum smear 
microscopy and culture results remained negative, so the 
continuation phase of treatment was initiated. The daily 
regimen consisted of ethambutol (800 mg), pyrazinamide 
(1,600 mg), prothionamide (500 mg), moxifloxacin (400 
mg), and clofazimine (100 mg).
In May 2014, after 6 months of treatment, the boy re-
turned to school while still receiving treatment. In August 
2014, the regimen was completed without incident, and at a 
6-month follow-up, the boy had not experienced a relapse. 
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According to study protocol, he will be followed for 1 year 
posttreatment to monitor for relapse.
The shortened treatment regimen has several potential 
benefits for children. The shorter treatment period enables 
an earlier return to school and social activities, the shorter 
duration of anti-TB injectable drug use may lessen ototox-
icity, and fewer adverse effects and shorter duration could 
improve treatment adherence.
The reluctance to include children in TB research stud-
ies may result from difficulties in confirming a diagnosis 
(due to paucibacillary disease and difficulty in obtaining 
specimens); such confirmation is often a prerequisite for 
treatment. Other barriers include lack of second-line TB 
drug formulations and pharmacokinetic data for children, 
ethics review issues, and informed and parental consent is-
sues. Clinicians and TB program managers could consider 
the 9-month treatment regimen for children. We advocate 
inclusion of children of all ages in research investigating 
the efficacy and safety of a 9-month regimen and emphasize 
the importance of separately reporting data for children.
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To the Editor: Sporolactobacillus laevolacticus, for-
merly known as Bacillus laevolacticus, is a gram-positive, 
acid-tolerant, catalase-positive, facultatively anaerobic and 
mesophilic bacteria initially isolated from the rhizosphere 
of wild plants (1,2). However, there have been no reports 
of its isolation from humans. We report S. laevolacticus 
associated with a wound infection and cellulitis in a patient 
hospitalized in Marseille, France.
In March 2015, a 47-year-old man with no underlying 
disease was admitted to the emergency unit of the North 
Hospital in Marseille, France. He had an infected wound 
on his right foot that occurred after he jogged barefoot 
during a vacation in Comoros, but the patient did not 
know how he obtained the wound and had not taken any 
antiinflammatory drugs. The foot became swollen, red, 
hot, and painful. He visited a doctor during his vacation 
and was prescribed antiinflammatory drugs and antimi-
crobial drugs, including a second-generation cephalospo-
rin and ofloxacin.
The patient returned to Marseille, but the infection 
persisted. At admission, the patient was apyretic but had 
high levels of C-reactive protein (85.7 mg/L [reference 
range 1–3 mg/L]) and fibrinogen (8.35 g/L), which indi-
cated inflammation. His leukocyte count was normal (9.29 
×109 cells/L) but his procalcitonin level (0.19 µg/L) was 
increased, which suggested that the infection had not been 
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